Wells Fargo & Company Vincerx Pharma, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 160 shares of VINC stock, worth $104. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160
Previous 133
20.3%
Holding current value
$104
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VINC
# of Institutions
40Shares Held
8.46MCall Options Held
0Put Options Held
0-
Sage Rhino Capital LLC1.7MShares$1.11 Million2.1% of portfolio
-
Octagon Capital Advisors LP New York, NY1MShares$650,0000.79% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct955KShares$620,6370.01% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$579,6170.12% of portfolio
-
Bank Of America Corp Charlotte, NC701KShares$455,9240.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $13.8M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...